Short Summary
The PTAB issued a Final Written Decision finding all 13 claims unpatentable by preponderance of the evidence. The Board found that the challenged claims were obvious over various combinations of prior art references, including Weaver combined with Lee ’053 and Song.
Detailed Summary
In this IPR, the Petitioner successfully demonstrated that the patent-in-suit claims related to pixel structure/OLED devices were unpatentable under 35 U.S.C. §§ 102 and 103. The Board adopted a broad construction of 'auxiliary electrode,' allowing for power lines or bus lines, which facilitated the finding that POSITAs would have been motivated to combine references like Weaver with Lee ’053 or Song to achieve lower resistance and voltage drop in OLED structures.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in BOE Technology Group Co., LTD vs Optronic Sciences, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
GLOBALFOUNDRIES Inc. et al.vsOAK IP LLC
Globalfoundries and Oak IP LLC settled their IPR dispute over U.S. Patent 10,937,880 before the Board instituted trial. The Board granted the joint motion to terminate and treated the settlement agreement as confidential.
Geotab Inc. et al.vsFractus, S.A.
Geotab has petitioned the PTAB to invalidate all twenty claims of Fractus’s ’200 antenna patent, citing obviousness over Dou and Jing and lack of written description for 4G‑related features. The petition seeks institution of the IPR and cancellation of the claims.
Samsung Electronics Co., Ltd. et al.vsWilus Institute of Standards and Technology Inc.
Samsung Electronics challenged Wilus Institute's patent claims (1-14) for obviousness over prior art related to Wi-Fi signaling standards. The PTAB found the Petitioner had a reasonable likelihood of prevailing, instituting the IPR on all 14 claims.
Tessell, Inc.vsNutanix, Inc.
Petitioner Tessell, Inc. filed an authorized response opposing Nutanix, Inc.’s request to reverse the PTAB’s institution of IPR2025-00298. The brief argues no unfair dealing, cites settled expectations for early‑filed patents, and asserts that discretionary denial under §325(d) is improper.
Aquestive Therapeutics, Inc.vsIono Pharma, LLC
Aquestive Therapeutics has filed an IPR petition seeking to invalidate claims 1‑3 of Iono Pharma’s ‘437 patent covering sublingual/ buccal epinephrine prodrugs. The challenger relies on obviousness over multiple prior‑art references, including Truelove patents, an academic paper, and the Almoazen paper.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.